A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Trial Profile

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms ATTAIN
  • Sponsors Biogen
  • Most Recent Events

    • 19 Jun 2018 Results of subgroup analysis of ADVANCE/ATTAIN presented at the 4th Congress of the European Academy of Neurology
    • 27 Apr 2018 Results of a subgroup analysis from ADVANCE, ATTAIN, TEMSO and TOWER studies comparing the clinical outcomes of peginterferon beta-1a and teriflunomide in DMT niave RMS patients, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results comparing the efficacy of subcutaneous (SC) peginterferon beta-1a and oral teriflunomide in patients from four randomised trials (ADVANCE, ATTAIN, TEMSO and TOWER), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top